MarketsNovember 13, 20265 min read

American Shared Hospital Services' Q3 Loss Widens; Guadalajara Start Moves to Mid-2027

American Shared Hospital Services increased third-quarter 2026 revenue 6.3% to about $7.6 million, but its net loss widened to $620,000 as margins fell and financing-related expenses rose. On its November 12 earnings call, management also pushed the expected start of patient treatments at its Guadalajara joint venture to mid-2027 and outlined continuing work on its Fifth Third Bank financing.

lake-ubemkbtzelugrrtocnlwolb9-1e17111e-da8a-4af6-8c6d-30b09fbdac71-0.webp

Revenue gains fail to lift earnings

The company lost $0.09 per diluted share in the quarter, compared with a net loss of $17,000 a year earlier. Investing.com reported that analysts had expected a $0.03 per-share profit and that the stock fell 11.02% in premarket trading to $1.05 from its previous close of $1.18.

Direct Patient Services accounted for the revenue growth. The segment brought in $4.6 million during the quarter, a 13.6% year-over-year increase, and $13.5 million over the first nine months, up 27%. Medical Equipment Leasing revenue was slightly below year-earlier levels at about $3.0 million for the quarter and $9.6 million for the nine-month period. Total nine-month revenue reached $23.1 million, up 13.7% from $20.3 million.

Despite the higher sales, quarterly gross profit declined to about $1.5 million from $1.6 million, and gross margin narrowed to 19.9% from 22.1%. Selling and administrative expenses increased to roughly $1.8 million from $1.5 million, largely reflecting legal, banking and consulting work on the credit agreement and capital structure.

Quarterly EBITDA fell to approximately $1.4 million from $1.9 million. For the first nine months, the net loss attributable to the company widened to $1.7 million, or $0.26 per diluted share, from $922,000, or $0.14 per diluted share. Adjusted EBITDA for that period declined to $3.8 million from $4.6 million.

Executive Chairman Ray Stachowiak said further gross-margin efficiencies were possible. He attributed pressure on operating profitability to the elevated advisory and banking expenses and said operating margins should improve once the Fifth Third relationship is resolved and those costs end.

Lender agreement sets a June 2027 deadline

The July agreement with Fifth Third Bank provides forbearance from certain rights and remedies through June 30, 2027. That is a more defined arrangement than management described earlier in the year, when it said lender discussions were progressing well and a potential extension was under consideration. Management said it must continue meeting specified milestones while working with lenders and other stakeholders on alternatives.

Alongside the July 2026 Third Amendment to the bank credit agreement, AMS obtained $2.0 million in subordinated financing to add liquidity. The lender, RCS/TIG Holdings LLC, is controlled by Stachowiak.

At September 30, cash equivalents and restricted cash totaled approximately $9.5 million, compared with $3.7 million at December 31, 2025. Operations generated about $5.8 million in cash during the first nine months. The net current portion of long-term debt declined to $15.6 million from $17.3 million at year-end.

The working capital deficit narrowed to about $4.6 million from $5.7 million over the same period. Equity attributable to AMS stood at $22.6 million, equivalent to about $3.40 per share on 6.65 million shares outstanding.

Asked about the financing situation, Stachowiak pointed to approximately $15 million owed to Fifth Third at September-end, the $9.5 million cash balance and nine-month operating cash generation. He said those figures gave him confidence that the company could reach a solution.

Treatment volumes show a mixed picture

Gamma Knife procedures rose approximately 11% year over year in both the quarter and the first nine months. Domestic volume increased 13.1% in the quarter, while international volume in Peru and Ecuador grew 8.9%. Those two international markets recorded 30.7% growth over the nine-month period.

AMS completed its Peru facility's upgrade to a Gamma Knife Esprit system in June 2025. The company said the system reduced treatment times, improved treatment efficiency and helped support higher procedure volume.

Radiation therapy revenue increased at the three Rhode Island facilities and the Puebla, Mexico, facility in both reporting periods, despite fewer procedures. Their combined quarterly procedure count fell to 7,143 from 7,355 a year earlier; the nine-month count declined to 19,788 from 20,401. In discussing Rhode Island's optimization, Stachowiak said revenue and procedure-volume gains had not produced as much benefit as expected and that further operating efficiencies remained available.

Proton Beam Radiation Therapy, or PBRT, produced $2.0 million in quarterly revenue, down from $2.1 million a year earlier. Treatment fractions declined to 960 from 1,150. Nine-month PBRT revenue was higher than a year earlier, with management attributing fluctuations in volume partly to scheduling and other quarter-to-quarter factors.

Management described demand across the treatment platform as healthy and said it was pleased with the company's progress. Its operating priorities include increasing facility utilization, strengthening clinical and administrative support and referral relationships, improving revenue-cycle execution, and controlling costs.

Guadalajara delay and selective project spending

The Hospital San Javier joint venture in Guadalajara is now expected to start treating patients in mid-2027, rather than begin operations in late 2026 as management had expected earlier in the year. The project will replace the hospital's existing Gamma Knife Perfexion system with a Gamma Knife Esprit. Management said the site will be one of only three Gamma Knives in Mexico.

In Rhode Island, the Bristol linear-accelerator project and Johnston proton-therapy project remain in the design stage, with little capital spending incurred to date. AMS is pursuing an asset-light approach for the Johnston PBRT project.

Stachowiak expressed confidence in the existing Rhode Island facilities and the two projects with CON approval. However, he said AMS would pursue other pipeline opportunities less aggressively until it resolves its creditor relationship with Fifth Third.

The company is led by Interim Chief Executive Officer Craig Tagawa, with Alexis Wallace serving as Interim Chief Financial Officer and Chief Accounting Officer and Stachowiak as Executive Chairman. Management provided no numerical outlook, saying its focus remains on utilization, operating performance, cash flow and financing arrangements.

lake-ubemkbtzelugrrtocnlwolb9-1cd6d7ad-5fd4-4ab2-9bec-d92899ff80c6-0.webp
Markets

Oxxo Closes 140 Mexican Stores as Review Slows Expansion

Oxxo added just 51 stores to its Mexican network in the third quarter of 2026 after closing 140 locations and opening 191. Owner Femsa said its review of older, weaker-performing shops would continue to affect the fourth quarter, leaving the chain like...

Sofía HerreraNov 9, 20263 min
lake-4912c530-dbcb-4401-9945-21f74c3d60ac-0.png
Markets

Rotoplas Narrows Third-Quarter Loss as EBITDA Rises 35.4%

Grupo Rotoplas nearly broke even in the third quarter of 2026, reporting a net loss of 2 million Mexican pesos versus 198 million pesos a year earlier. Sales increased 9.6% to 2.927 billion pesos, while EBITDA reached 385 million pesos, up 35.4%.

Sofía HerreraOct 21, 20264 min
Back to Markets